Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Nat Rev Nephrol ; 18(11): 724-737, 2022 11.
Article in English | MEDLINE | ID: covidwho-2000908

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has disproportionately affected patients with kidney disease, causing significant challenges in disease management, kidney research and trainee education. For patients, increased infection risk and disease severity, often complicated by acute kidney injury, have contributed to high mortality. Clinicians were faced with high clinical demands, resource shortages and novel ethical dilemmas in providing patient care. In this review, we address the impact of COVID-19 on the entire spectrum of kidney care, including acute kidney injury, chronic kidney disease, dialysis and transplantation, trainee education, disparities in health care, changes in health care policies, moral distress and the patient perspective. Based on current evidence, we provide a framework for the management and support of patients with kidney disease, infection mitigation strategies, resource allocation and support systems for the nephrology workforce.


Subject(s)
Acute Kidney Injury , COVID-19 , Humans , Pandemics , SARS-CoV-2 , Renal Dialysis , Acute Kidney Injury/epidemiology , Acute Kidney Injury/therapy , Kidney
3.
PLoS One ; 15(9): e0238831, 2020.
Article in English | MEDLINE | ID: covidwho-760701

ABSTRACT

INTRODUCTION: During the Covid-19 pandemic, major journals have published a significant number of Covid-19 related articles in a short period of time. While this is necessary to combat the worldwide pandemic, it may have trade-offs with respect to publishing research from other disciplines. OBJECTIVES: To assess differences in published research design before and after the Covid-19 pandemic. METHODS: We performed a cross-sectional review of all 322 full-length research studies published between October 1, 2019 and April 30, 2020 in three major medical journals. We compared the number of randomized controlled trials (RCTs) and studies with a control group before and after January 31, 2020, when Covid-19 began garnering international attention. RESULTS: The number of full-length research studies per issue was not statistically different before and after the Covid-19 pandemic (from 3.7 to 3.5 per issue, p = 0.17). Compared to before January 31, 2020, 0.7 fewer non-Covid-19 studies per issue were published versus after January 31, 2020 (p<0.001), a change that was offset by Covid-19 studies. Among non-Covid-19 studies, 0.9 fewer studies with a control group per issue were published after January 31, 2020, with RCTs contributing to nearly all the decline (p<0.001, p = 0.001, respectively). In the same timeframe, non-Covid-19 studies without a control group and non-Covid-19 studies without randomization experienced relatively small changes that did not meet our threshold for statistical significance (increases of 0.1 and 0.1 per issue, p = 0.80, p = 0.88, respectively). LIMITATIONS: Using a simple heuristic for assessing research design and lack of generalizability to the general medical literature. CONCLUSIONS: In summary, the increase in Covid-19 studies coincided with a decrease of mostly non-Covid-19 RCTs.


Subject(s)
Coronavirus Infections/pathology , Pneumonia, Viral/pathology , Research/trends , Betacoronavirus/isolation & purification , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , Cross-Sectional Studies , Humans , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , Randomized Controlled Trials as Topic , SARS-CoV-2
4.
Adv Chronic Kidney Dis ; 27(5): 390-396, 2020 09.
Article in English | MEDLINE | ID: covidwho-729001

ABSTRACT

The coronavirus (coronavirus disease-2019) pandemic has changed care delivery for patients with end-stage kidney disease. We explore the US healthcare system as it pertains to dialysis care, including existing policies, modifications implemented in response to the coronavirus disease-2019 crisis, and possible next steps for policy makers and nephrologists. This includes policies related to resource management, use of telemedicine, prioritization of dialysis access procedures, expansion of home dialysis modalities, administrative duties, and quality assessment. The government has already established policies that have instated some flexibilities to help providers focus their response to the crisis. However, future policy during and after the coronavirus disease-2019 pandemic can bolster our ability to optimize care for patients with end-stage kidney disease. Key themes in this perspective are the importance of policy flexibility, clear strategies for emergency preparedness, and robust health systems that maximize accessibility and patient autonomy.


Subject(s)
COVID-19 , Health Policy , Kidney Failure, Chronic/therapy , Nephrology , Renal Dialysis/methods , Telemedicine/methods , Ambulatory Care Facilities , Anastomosis, Surgical , Arteries/surgery , Blood Vessel Prosthesis Implantation , Centers for Medicare and Medicaid Services, U.S. , Computer Security , Delivery of Health Care/methods , Delivery of Health Care/standards , Disaster Planning , Health Services Accessibility , Hemodialysis Solutions/supply & distribution , Hemodialysis, Home/methods , Hemodialysis, Home/standards , Humans , Organization and Administration/standards , Personal Autonomy , Personal Protective Equipment , Quality Assurance, Health Care , Reimbursement Mechanisms , Renal Dialysis/instrumentation , Renal Dialysis/standards , SARS-CoV-2 , Telemedicine/standards , United States , Veins/surgery
SELECTION OF CITATIONS
SEARCH DETAIL